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Abstract
Aims Hypertrophic cardiomyopathy (HCM) is a frequent
cause of sudden cardiac death (SCD) due to exercise-related
ventricular arrhythmias (ERVA); however the pathological
substrate is uncertain. The aim was to determine the
prevalence of ERVA and their relation with fibrosis as
determined by cardiac magnetic resonance imaging (CMR)
in carriers of an HCM causing mutation.
Methods We studied the prevalence and origin of ERVA
and related these with fibrosis on CMR in a population of
31 HCM mutation carriers.
Results ERVA occurred in seven patients (23%) who all
showed evidence of fibrosis (100% ERVA(+) vs. 58%
ERVA(-), p=0.04). No ventricular tachycardia or ventricu-
lar fibrillation occurred. In patients with ERVA, the extent
of fibrosis was significantly larger (8±4% vs. 3±4%, p=
0.02). ERVA originated from areas with a high extent of
fibrosis or regions directly adjacent to these areas.
Conclusions ERVA in HCM mutation carriers arose from
the area of fibrosis detected by CMR; ERVA seems closely
related to cardiac fibrosis. Fibrosis as detected by CMR
should be evaluated as an additional risk factor to further
delineate risk of SCD in carriers of an HCM causing
mutation.
Keywords Hypertrophic cardiomyopathy.Magnetic
resonance imaging.Exercise.Fibrosis.Arrhythmias
Introduction
Hypertrophic cardiomyopathy (HCM) is a common
inherited cardiac disorder which is estimated to occur
in one out of 500 patients within the general population
[1]. An autosomal dominant mutation is found in approx-
imately 50–60% of cases, most frequently in genes that
code for sarcomeric proteins [2]. These mutations often
lead to thickening of the left ventricular (LV) wall,
myocyte disarray, and cardiac fibrosis [3]. Important
clinical consequences of HCM are heart failure and
potentially life-threatening ventricular arrhythmias. HCM
is the most common cause of sudden cardiac death
(SCD) under the age of 35 years, especially in young
athletes. About one sixth of the cases of SCD occur
during or immediately after moderate to severe physical
activity [4, 5].
Because of the phenotypic heterogeneity of HCM it is
important to find predictors and mechanisms that can
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precise mechanism of underlying arrhythmias remains
unknown and it is currently unsettled whether SCD is
triggered by pro-arrhythmic changes in hypertrophied
cardiac myocytes themselves or rather by changes in the
myocardial structure due to myocardial fibrosis [8–11].
Since SCD in HCM patients is often related to exercise
and to fibrosis, we sought to determine the prevalence of
ventricular arrhythmias during exercise-ECG testing in a
population of proven carriers of an HCM causing mutation
and relate this to fibrosis as determined with cardiac
magnetic resonance imaging (CMR).
Materials and methods
Study patients
A cohort of 31 genetically proven HCM mutation carriers
(probands and family members) were seen between March
2004 and February 2008 in the Maastricht University
Medical Center, the Netherlands. We included all carriers,
symptomatic and asymptomatic, where both a CMR and
exercise test were available for analysis.
CMR
Patients were examined with a clinical 1.5T Gyroscan
Intera MRI scanner (Philips Medical Systems, Best, the
Netherlands) equipped with a dedicated five-element
phased array surface coil and cardiac software. ECG-gated
multi-slice multi-phase images were acquired for functional
analysis during multiple breath holds using a steady-state
free precession sequence (slice thickness 6 mm, slice gap
4 mm, repetition time/echo time 3.8/1.9 ms, flip angle 50°,
field of view 350 mm, matrix 256×256, 22–25 phases per
cardiac cycle) in vertical long-axis (VLA), horizontal long-
axis (HLA), LVoutflow tract (LVOT) view and contiguous
short-axis (SAX) slices covering the entire left ventricle.
Ten minutes after 0.2 mmol/kg intravenous contrast
administration (Gadolinium-DTPA, Magnevist, Schering,
Berlin, Germany) a Look-Locker (LL) sequence was
applied in SAX orientation to determine the inversion time
to optimally ‘null’ LV myocardium for the subsequent scan.
Immediately after the LL scan, late gadolinium enhance-
ment (LGE) multislice images were obtained using a 3D
inversion-recovery gradient-echo sequence, covering the
entire LV in the HLA, VLA and SAX orientation.
Functional analysis and wall thickness
CMR images were analysed with commercially available
software (CAAS MRV 3.0, Pie Medical Imaging BV,
Maastricht, the Netherlands). Endocardial and epicardial
contours were manually traced in end-diastolic and end-
systolic phases on SAX CINE images to determine end-
diastolic volume and end-systolic volume, ejection fraction
and LV end-diastolic (LVED) mass. Where appropriate
LVED was indexed to body surface area. The maximal end-
diastolic LV wall thickness (LVEDWT(max)) was taken as
the greatest dimension of the LV wall at any site.
Structural abnormalities (Fibrosis)
On the LGE images, the presence and localisation of
fibrosis (i.e. hyperenhancement) was assessed by two
independent observers who were blinded to the clinical
and exercise ECG results. Any discrepancy in analysis
between the two readers was then adjudicated by a third
observer. The presence of fibrosis was accepted when it
was reproducibly observed in all orientations. These areas
of fibrosis were subsequently quantified in SAX orientation
using a signal intensity (SI) cut-off of at least 5 SD above
the SI of remote and adequately ‘nulled’ myocardium [12].
The extent of fibrosis was expressed as percent of LV mass
and on a segmental basis according to the American Heart
Association (AHA) 17 segment model [12, 13]. Because
measurements of the apex were often unreliable, this
segment (segment 17) was excluded from further analysis.
In addition, the most basal slice having circumferential
myocardial muscle at both the end-diastolic and end-
systolic phase was selected as the base of the left ventricle
to prevent including the LVOT in the measurements. Based
on the mean extent of fibrosis per patient, each segment
was classified as either having a high (more than or equal
to) or low (less than the mean) extent of fibrosis.
Exercise test
All patients underwent a symptom-limited treadmill
exercise test according to the Bruce protocol [14].
Standard blood pressure and 12-lead ECG monitoring
were performed. Medical therapy at the time of the
exercise test was registered. Exercise related ventricular
arrhythmias (ERVA) were defined as ventricular premature
beats (VPBs), ventricular tachycardia (VT ≥3b e a t sa n d
frequency ≥100 beats/min) and ventricular fibrillation
(VF), occurring during exercise and the post-exercise
recovery period. Regarding these VPBs, the number,
morphology, bigeminy and time of occurrence during the
exercise test were analysed.
Origin of ERVA
The origin of ERVA was determined according to the
diagram in Fig. 1 based on the AHA 17 segment model by
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clinical and CMR data [13]. Patients were categorised into
two groups, according to presence or absence of ERVA.
Within each patient the origin of ERVA was compared with
the site of fibrosis within the 17 segment model (Fig. 2).
Statistical analysis
Data are expressed as mean ± SD. Clinical and demo-
graphic characteristics of the ERVA and non-ERVA groups
were compared using the Mann-Whitney U test for
continuous variables, and the χ
2 test for categorised
variables expressed as proportions (or Fisher’s exact test
for subgroups containing ≤5 observations). The SPSS
software version 12.0 (SPSS Inc., Chicago, Illinois) was
used for all analyses. A p value of ≤0.05 was considered
statistically significant.
Results
Baseline characteristics are shown in Table 1. Thirty-one
patients were studied with a mean age of 38±13 years
(range 16 to 65 years) and of whom 20 were male (65%).
These patients carried five different mutated genes, one
patient carried a double-heterozygous mutation. Mean
LVED mass and LVEF were 76±23 g/m
2 and 67±5%
respectively. LVEDWT(max) was 20±7 mm (range 9 to
32 mm). Twenty-three (74%) patients had an LVEDWT
(max) of ≥15 mm. Fibrosis was present in 21 (68%)
Fig. 1 Analysis method to determine the origin of ventricular
arrhythmias. Localisation within the left ventricle: according to the
AHA 17 segment model of the left ventricle [13]. LBBB left bundle
branch block, etc. Neg negative, Pos positive, RBBB right bundle
branch block, RV right ventricle
Fig. 2 Example of exercise
related arrhythmias and fibrosis
in one patient. Late gadolinium
enhanced (LGE) short axis image
(a) showing fibrosis in the basal
anteroseptal segment (arrow). In
this patient, a ventricular prema-
ture beat originated from the
corresponding segment or nearby
this segment in the right ventric-
ular outflow tract (b)
170 Neth Heart J (2011) 19:168–174patients. In these patients, the extent of fibrosis was 4.9±
4.3% of LV mass. ERVA (VPBs but not VT or VF)
occurred in 7 (23%) patients. One patient had a bigeminy
and couplet during the recovery phase.
All patients with ERVA had myocardial fibrosis on
CMR, whereas fibrosis was only observed in 58% of the
patients without ERVA (100% vs. 58%, p=0.04). In patients
with ERVA, the extent offibrosis was significantly larger than
in patients without ERVA (8±4% vs. 3±3%, p=0.02).
The LVEDWT(max) and NT-proBNP levels did not
significantly differ between patients with and without ERVA
(23±7 mm vs. 19±7 mm, p=0.2 and 87±53 pmol/l vs. 62±
57 pmol/l, p=0.3, respectively).
No significant differences in concomitant β-blocker
therapy, gender, age or mutated gene were found between
patients with and without ERVA. All patients with ERVA
had one or more risk factors for SCD (100% vs. 58%, p=
0.04) (Table 2)[ 15]. There was no significant difference in
the presence of fibrosis between the carriers of the different
gene mutations (p=0.7).
Origin of ERVA
In four patients ERVA originated from the same segment, as
the segment with a high extent of fibrosis (Table 3). In the
remaining three patients the ERVA were derived from
segments immediately adjacent to segments with a high
extent of fibrosis.
Table 1 Study patients and subgroups according to exercise related ventricular arrhythmias
Characteristics All patients (n=31) ERVA status p value
a
ERVA (+) (n=7) ERV A (−)( n=24)
Age (years) 38±13 37±6 38±15 NS
Male gender, n (%) 20 (65) 5 (71) 15 (63) NS
More than 1 SCD risk factor, n (%) 21 (68) 7 (100) 14 (28) 0.04
Mutations, n (%) NS
MYH7 12 (37)
b 2 (29) 10 (40)
b
MYBPC3 7 (23) 4 (57) 3 (13)
TPM1 9 (29) 1 (14) 8 (33)
MYL2 2 (7) 0 (0) 2 (8)
CSRP3 2 (5)
b 0 (0) 2 (6)
b
NT-proBNP, pmol/l 70±56 87±53 62±57 NS
CMR
LVEF, % 67±5 69±3 67±6 NS
LVMi, g/m
2 76±23 95±33 71±17 NS
LVEDWT(max), mm 20±7 23±7 19±7 NS
Fibrosis, n (%) 21 (68) 7 (100) 14 (58) 0.04
Extent of fibrosis, % 5±4 8±4 3.4±3.6 0.02
Exercise test, n (%)
VT/VF 0 (0) 0 0
VPBs 7 (27) 7 0
Bigeminy and couplet 1 (3) 1 0
β-blocker therapy 9 (29) 3 (43) 6 (25) NS
CMR cardiac magnetic resonance imaging, CSRP3 cysteine and glycine-rich protein 3, ERVA exercise related ventricular arrhythmias, LV left
ventricle, LVEDWT(max) maximal end-diastolic left ventricle wall thickness, LVEF left ventricle ejection fraction, LVMi left ventricle mass index,
MYBPC3 myosin binding protein C, MYH7 myosin heavy chain 7, MYL2 myosin light chain 2, NS not significant, SCD sudden cardiac death,
TPM1 alpha tropomyosin 1, VF ventricular fibrillation, VPB ventricular premature beat, VT ventricular tachycardia
aThe p values reflect the comparison of patients with ERVA vs. those without ERVA
bOne patient carried double heterozygous gene mutations
Table 2 Relation between the number of risk factors for sudden
cardiac death and the presence of exercise related ventricular
arrhythmias
Number of risk factors ERVA (+) (n=7) ERV A (−)( n=24)
0, n (%) 0 (0) 10 (42)
1, n (%) 5 (71) 11 (46)
2, n (%) 1 (14) 2 (8)
3, n (%) 0 (0) 1 (4)
4, n (%) 1 (14) 0 (0)
ERVA exercise related ventricular arrhythmias
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fibrosis of patients with only ERVA during exercise and
patients with ERVA during recovery (10±3% vs. 7±7%, p=
0.7) and there was no significant difference between the
extent of fibrosis of patients with one ERVA and patients
with more than one ERVA (8±7% vs. 10±3%, p=0.9).
Discussion
Widespread genetic testing identifies large numbers of
carriers of mutations that cause HCM; these carriers often
have no or few symptoms. Exercise is considered an
important risk factor of SCD in these subjects, but the
precise risk of exercise in mutation carriers is not fully
defined. The purpose of our study was to investigate the
relation between fibrosis and ERVA in a population of
HCM mutation carriers. ERVA were found in about one
fifth of the patients. Interestingly, we found that ERVA
exclusively occurred in patients who demonstrated fibrosis
on CMR, and that these arrhythmias originated from areas
of fibrosis or regions directly adjacent to these areas.
Patients with ERVA had significantly more fibrosis on
CMR as compared with patients without ERVA. In
addition, all patients with ERVA also had one or more risk
factors for SCD. ERVA were not related to age, gender,
ejection fraction, NT-proBNP levels, LVEDWT(max) or
treatment with β-blockers.
Our study suggests that ERVA is a marker of arrhythmo-
genic cardiac fibrosis as represented by their spatial
relationship as well as the higher load of late enhancement
on gadolinium-enhanced CMR in arrhythmogenic areas.
Earlier studies also suggested a relation between ventric-
ular arrhythmias and myocardial fibrosis in patients with
HCM [10, 16, 17]. In these studies the prevalence of late
enhancement was between 41% [17]a n d7 9 %[ 10], which is
similar to our study. In contrast to these studies, we
considered ERVA rather than spontaneous arrhythmias or
arrhythmias on ambulatory monitors. Besides that we used a
population of proven carriers of pathogenic HCM mutations.
In 2003, Moon et al. [10] described that HCM patients with
≥2 risk factors for SCD including nonsustained ventricular
tachycardia on Holter monitoring showed a greater extent of
fibrosis. Adabag et al. [17] showed that VPBs on Holter
monitoring are related to the presence of fibrosis, but not to
the extent of fibrosis. Recently Kwon et al. [15]s h o w e dt h a t
patients with VT had a significantly higher extent of fibrosis,
which is in line with our present findings.
Two other Dutch studies have already described the
importance of cardiological evaluation for asymptomatic
carriers of HCM causing mutations. Christiaans at al.
described a population of 235 asymptomatic mutation
carriers with a mutation in myosin binding protein C
(MYBPC3); after first cardiological evaluation almost one-
quarter were diagnosed with HCM and more than one-
tenth of the carriers were at risk for SCD [18]. Michels et
al. found an even higher number of asymptomatic
mutation carriers who received the diagnosis HCM [19].
They also described the presence of SCD risk factors in
carriers with and without HCM. In the same line, Ho et
a l .s h o w e da ne a r l yp r o f i b r o tic response of mutation
carriers but without left ventricular hypertrophy [20].
The current risk stratification used for HCM identifies a
number of high-risk patients for SCD, but unfortunately
still a substantial number of HCM patients die suddenly
[21]. Fibrosis as detected by CMR is increasingly recog-
nised as a risk factor for SCD in HCM, but routine
screening is not yet advised [9, 15, 16, 21, 22]. Our data
lend further support to the idea that myocardial fibrosis in
HCM is related to ERVA. However, this study cannot
answer whether these ERVA are related to more life-
threatening ventricular arrhythmias.
In population-based cohorts with coronary heart disease,
VPBs do predict an increased risk of death, but VPBs that
Table 3 Relation between the origin of exercise related ventricular arrhythmias and the localisation of left ventricular fibrosis
Patient Origin of the VA
a Segment with a high extent of fibrosis
b Relation between origin of the VA and
the segments of fibrosis
1 2 2, 4, 8, 10 Same segment
2 15/16 2, 8, 10 Adjacent segment
3 8 2, 3, 9, 10 Adjacent segment
4 8 1, 2, 4, 8, Same segment
5 10/11 1, 2, 8, 10 Same segment
6 14 1, 2, 7, 8, 10, 12 Adjacent segment
7 10/11 3, 4, 5, 10, 11, 12,14 Same segment
VA ventricular arrhythmias
aAccording to Fig. 1
bAccording to the AHA 17 segment model of the left ventricle [13]
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even better predictor of an increased risk of death compared
with VPBs during exercise [23–25].
There are important limitations to this retrospective study
that need to be taken into account. Most importantly, the fact
that the registry was undertaken by a referral centre may have
resulted in a referral bias towards more severely affected
patients. Moreover, it cannot be excluded that there was a
selection bias towards the selection of patients with both a
CMR and exercise test. This study is limited by its size, and
lack of follow-up. As a result, it cannot answer the question
whether ERVA should also be considered as a marker of high
risk of SCD in the HCM population, as it is in patients with
coronary artery disease. However, it may provide the
necessary initial observation to fuel a larger study into the
predictive role of ERVA and to validate our findings.
The ERVA that were observed originated either from a
segment with a high extent of fibrosis or from a segment
directly adjacent to this. This imprecision may be explained
by the fact that the analysis of the origins of the VPBs is an
approximation provided by 12-channel ECG readings, but
also by the fact that the exit point is at the edge of the fibrosis
area and not necessarily in the area itself. In addition,
electrocardiographic and anatomical orientation by CMR are
not fully congruent and may lead to imprecision of the origin
of the VPB and the localisation of fibrosis.
Conclusion
A substantial proportion of carriers of an HCM causing
mutation may show ERVA which—in turn—is associated
with a significantly higher extent of ventricular fibrosis. In
addition, there was a significant spatial relationship be-
tween ERVA and fibrosis supporting the notion that
increased fibrosis is arrhythmogenic and possibly related
to increased mortality. Future studies are needed to address
whether increased late enhancement on CMR represents an
increased risk of SCD in HCM mutation carriers.
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